ICON CLINICAL RESEARCH (U.K.) LIMITED
Get an alert when ICON CLINICAL RESEARCH (U.K.) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-03-29 (in 10mo)
Last made up 2026-03-15
Watchouts
Cash
£467K
-40.3% vs 2023
Net assets
£77M
+12.5% vs 2023
Employees
845
+56.5% vs 2023
Profit before tax
£8M
+195% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £82,557,199 | £105,267,626 | |
| Operating profit | -£8,228,076 | £7,693,368 | |
| Profit before tax | -£8,187,752 | £7,776,686 | |
| Net profit | -£9,850,062 | £5,466,676 | |
| Cash | £782,287 | £466,661 | |
| Total assets less current liabilities | — | — | |
| Net assets | £68,442,801 | £76,999,542 | |
| Equity | £68,442,801 | £76,999,542 | |
| Average employees | 540 | 845 | |
| Wages | £39,385,855 | £53,141,303 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -10.0% | 7.3% | |
| Net margin | -11.9% | 5.2% | |
| Current ratio | 1.15x | 1.34x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt over its ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.”
Group structure
- ICON CLINICAL RESEARCH (U.K.) LIMITED · parent
- VSK (Kenilworth) Limited 100%
- ICON Development Solutions Limited 100%
- Aptiv Solutions (UK) Limited 100%
- ICON Clinical Research (U.K.) No. 3 Limited 100%
- ICON Clinical Research (U.K.) No. 2 Limited 100%
- Accellacare South Africa (PTY) LTD 49%
- DOCS International UK Limited 100%
- ICON Clinical (UK) Limited 100%
Significant events
- “On 27 August 2024, ICON Holdings Clinical Research International Limited transferred its nominee shareholding in the Company to the beneficial owner, ICON Clinical International Limited.”
- “On 30 September 2024, ICON Clinical International Limited merged into its sole shareholder, ICON Holdings Unlimited Company. As a result of the merger by absorption ICON Holdings Unlimited Company became the sole shareholder of the Company.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 15 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| FOX, Erina | Secretary | 2013-02-14 | — | — |
| HOLLYWOOD, Simon | Director | 2023-10-12 | Jan 1980 | Irish |
| MACDONALD, John | Director | 2022-12-09 | Mar 1967 | British |
| VAN WYK, Quintin, Dr | Director | 2013-11-13 | Aug 1970 | British |
Show 15 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CLIMAX, John, Dr | Secretary | — | 2009-12-17 |
| WHALVIN, Julia | Secretary | 2009-12-17 | 2013-01-23 |
| BROWN, Tracy | Director | 2023-06-19 | 2025-03-14 |
| CLIMAX, John, Dr | Director | — | 2009-12-17 |
| GLEESON, Michael | Director | 2011-12-21 | 2022-10-21 |
| GRAY, Peter | Director | 2004-01-19 | 2009-12-17 |
| HARRIS, Joy, Ms. | Director | 2013-03-25 | 2015-04-16 |
| HARTE, Brendan | Director | 2009-12-17 | 2023-10-12 |
| LAMBE, Ronan, Dr | Director | — | 2009-12-17 |
| LEFTWICH, Robert James | Director | 2021-12-14 | 2023-06-19 |
| MORGAN, Alan Stuart | Director | 2009-12-17 | 2011-10-28 |
| MORGAN, Allan, Dr | Director | — | 2004-01-19 |
| WALTHAM, Lynda Ann | Director | 2009-12-17 | 2013-03-25 |
| WHALVIN, Julia Caroline | Director | 2011-12-21 | 2013-01-23 |
| WILD, Diane Jacqueline | Director | 2013-11-13 | 2014-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Icon Clinical Research Holdings (U.K.) Limited | Corporate entity | Shares 50–75%, Voting 50–75% | 2025-05-31 | Active |
| Icon Public Limited Company | Corporate entity | Shares 75–100% | 2016-04-06 | Ceased 2025-05-31 |
Filing timeline
Last 20 of 133 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-06-04 RESOLUTIONS Resolution
- 2025-06-03 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-03-30 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-01-07 | AA | accounts | Accounts with accounts type full | |
| 2025-07-07 | SH01 | capital | Capital allotment shares | |
| 2025-07-07 | SH01 | capital | Capital allotment shares | |
| 2025-06-04 | RESOLUTIONS | resolution | Resolution | |
| 2025-06-03 | MA | incorporation | Memorandum articles | |
| 2025-06-02 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-06-02 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-06-02 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2025-03-28 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-03-25 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-03 | AA | accounts | Accounts with accounts type full | |
| 2024-03-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-12-04 | AA | accounts | Accounts with accounts type full | |
| 2023-10-13 | AP01 | officers | Appoint person director company with name date | |
| 2023-10-13 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-04 | AP01 | officers | Appoint person director company with name date | |
| 2023-09-01 | TM01 | officers | Termination director company with name termination date | |
| 2023-03-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-02-07 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 9
- Capital events
- 2
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+27.5%
£82,557,199 £105,267,626
-
Cash
-40.3%
£782,287 £466,661
-
Net assets
+12.5%
£68,442,801 £76,999,542
-
Employees
+56.5%
540 845
-
Operating profit
+193.5%
-£8,228,076 £7,693,368
-
Profit before tax
+195%
-£8,187,752 £7,776,686
-
Wages
+34.9%
£39,385,855 £53,141,303
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers